← Leaderboards
Pui Chun Cheng
Tulane University Of Louisiana
$48,251
Attributed
$48,251
Total exposure
8
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $20.6K · FY2005–06$25K$18.8K$12.5K$6.3K$0
'05
'06
Funding mix
By agency
NIH$48,251 · 8
By mechanism
M01$48,251 · 8
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Patricia S Braly$22,399
- Alan Marshall Miller$44,720
- Ellen L Zakris$642,522
- Juan J. L. Lertora$4,837,795
- James Jackson$3,389,736
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyClinical ResearchHuman Therapy EvaluationHuman SubjectFemaleOvary NeoplasmsPaclitaxelCis Platinum CompoundPatient Oriented ResearchCombination ChemotherapyDoxorubicinDrug Administration RoutesDrug Adverse EffectAntineoplasticsCarboplatinTobacco AbuseFluorouracilCarcinomaHemoglobinSmokingQuality Of LifeCervix NeoplasmsPeritoneum NeoplasmNeoplasm /Cancer Radiation Therapy
Grant awards (11)
TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS COMBINATIONS IN PATIENTS WITH CANCER$2,331
M01 · FY2006 · RR · contact PI
GOG 203C: EVALUATION OF GLEEVEC IN TREATMENT OF CARCINOSARCOMA OF THE UTERUS$972
M01 · FY2006 · RR · contact PI
TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS COMBINATIONS IN PATIENTS WITH CANCER$15,826
M01 · FY2005 · RR
TRIAL OF DOXORUBICIN/CISPLATIN/PACLITAXEL IN RECURRENT ENDOMETRIAL CANCER$4,733
M01 · FY2005 · RR
Trial of Paclitaxel and Carboplatin Versus Combinations in Patients With Cancer$21,561
M01 · FY2004 · RR
Evaluation of CT-2103 in the Treatment of Ovarian Cancer$2,651
M01 · FY2004 · RR
SWOG S0200: Study of Pegylated Liposomal Doxorubicin$177
M01 · FY2004 · RR
RADIATION + CISPLATIN VS RADIATION + 5-FU IN CERVIX CA$0
M01 · FY2001 · RR
GOG 172:IV PACLITAXEL &CISPLATIN VS IV PACLITAXEL IN EPITHELIAL OVAR$0
M01 · FY2001 · RR
GOG 172:IV PACLITAXEL &CISPLATIN VS IV PACLITAXEL IN EPITHELIAL OVAR$0
M01 · FY2000 · RR
RADIATION + CISPLATIN VS RADIATION + 5-FU IN CERVIX CA$0
M01 · FY2000 · RR